Key result
Levosimendan significantly improves left ventricular ejection fraction and exercise tolerance in patients with heart failure, while demonstrating a favorable safety profile comparable to placebo.
Why the study?
Levosimendan has emerged as a potential therapeutic modulator for heart failure, prompting a systematic review of its efficacy and safety across different clinical settings.
Does levosimendan improve hemodynamics and clinical outcomes in patients with heart failure?
Systematic Review (n=1,200)
Does levosimendan improve hemodynamics and clinical outcomes in patients with heart failure?
Levosimendan demonstrates promising potential for improving hemodynamics, LVEF, and exercise tolerance across various heart failure settings with a favorable safety profile.
Supports levosimendan use in heart failure for LVEF and exercise gains; extends meta-analytic confirmation of efficacy and safety.
Levosimendan, a novel drug, a calcium-sensitizing inotrope, has emerged as a potential therapeutic modulator for heart failure (HF). This review appraises the efficacy and safety of levosimendan in managing HF, in different clinical settings. The study aims to examine the clinical outcomes reported in the selected trials to determine the effectiveness of levosimendan in improving key parameters related to HF. Seven relevant studies encompassing 1200 participants were identified from three databases. Inclusion criteria included clinical trials that investigated the therapeutic efficacy of levosimendan in the treatment of HF, and studies involving both adult and pediatric participants. Exclusion criteria involved studies with insufficient data, studies other than clinical trials, case reports, letters to the editor, conference papers, grey literature, and studies published in a language other than English. Upon evaluating the included studies, it was found that levosimendan shows improved hemodynamics and clinical efficacy in patients with severe septic cardiomyopathy. Levosimendan enhanced right ventricular (RV) function in patients with RV dysfunction after mitral valve (MV) surgeries and decreased the amount of N-terminal pro-B-type natriuretic peptide (NT-ProBNP) in non-ST elevated myocardial infarction (NSTEMI) patients with elevated NT-proBNP, all without increasing the overall cost or duration of hospitalization. Despite variations in study designs and participant characteristics, evidence suggests levosimendan significantly improves left ventricular ejection fraction (LVEF) and exercise tolerance measured by a six-minute walk distance. Notably, its safety profile appears favorable with minimal arrhythmic events and comparable rates of adverse effects to a placebo. This systematic review highlights levosimendan's promising potential for HF management, warranting further research to solidify its clinical role.
No takes yet. Share an insight, caveat, or question.
Sajjad et al. (2024) conducted a systematic review in Heart failure (n=1,200). Levosimendan vs. Placebo, milrinone, dobutamine, or no levosimendan was evaluated on Clinical outcomes related to heart failure (including hemodynamics, left ventricular ejection fraction, and exercise tolerance). Levosimendan significantly improves left ventricular ejection fraction and exercise tolerance in patients with heart failure, while demonstrating a favorable safety profile comparable to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: